Maximizing your time at the Fragment-Based Lead Discovery Conference San Diego, California, October
The Fragment Based Lead Discovery Conference is right around the corner! This is the 10th anniversary of the meeting founded by Vicki...
I-Corps at the NIH: What we learned and how it can help you obtain grants and grow your business!
So, you are contemplating your newest great idea for a product and are seeking investment ideally through the SBIR program. To write a...
Five Easy Steps to Submitting a New Grant
It’s that time of year again, we are back from summer vacation and thinking about submissions for the next NIH grant cycle. First up is...
How does Zenobia design it's shape diverse mixtures?
Why Screen as Mixtures? In many cases, it is much more efficient to screen as mixtures because it pares down the dataset to a manageable...
What is Crystallographic Screening and Why is it Making a Comeback?
What is Crystallographic Screening? Crystallographic screening is a method used to detect ligands that bind to a target protein. What...
Drugability Series, Part 1
PART 1: Fragments as a Pre-Screen to Assess Target Drugability This is the first in a series of blogs discussing the concept of using...
Diversity Series, Part 3
PART 3: How diverse are Zenobia's libraries? This is the last in a three-part series discussing Chemical Diversity in fragment library...
Diversity Series, Part 2
PART 2: What are the parameters for evaluating diversity? This is the second in a three-part series discussing chemical diversity. In...
Diversity Series, Part 1
PART 1: What is Chemical Diversity? This is the first in a three-part series discussing chemical diversity. In Part 1, we introduce the...
GoT Frags?
The "Guideline of Two" Over the past decade, a number of rules and calculated metrics have arisen in drug discovery. In particular, the...
